Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31412820 | 1.00 | ADRB2 (0.33) | ADRB2ADRB1ADRB3MAPTALDH1A1 | |
| SCHEMBL8223325 | 1.00 | ADRB2 (0.33) | ADRB2ADRB1ADRB3MAPTALDH1A1 | |
| SCHEMBL30496785 | 0.93 | ADRB2 (0.39) | ADRB2ADRB1ADRB3MAPTALDH1A1 | |
| SCHEMBL8223254 | 0.88 | MAPT (0.33) | ADRB2ADRB1ADRB3MAPTALDH1A1 | |
| SCHEMBL8212365 | 0.88 | MAPT (0.33) | ADRB2ADRB1ADRB3MAPTALDH1A1 | |
| SCHEMBL18228936 | 0.86 | MAPT (0.35) | ADRB2ADRB1ADRB3MAPTALDH1A1 | |
| SCHEMBL18228935 | 0.86 | MAPT (0.35) | ADRB2ADRB1ADRB3MAPTALDH1A1 | |
| SCHEMBL8219271 | 0.86 | MAPT (0.35) | ADRB2ADRB1ADRB3MAPTALDH1A1 | |
| SCHEMBL8222724 | 0.86 | MAPT (0.35) | ADRB2ADRB1ADRB3MAPTALDH1A1 | |
| SCHEMBL8213778 | 0.85 | MAPT (0.34) | ADRB2ADRB1ADRB3MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12589377-B2 | Encapsulated composition comprising core-shell microcapsules and process for its preparation | GIVAUDAN SA (CH) | 2026-03-31 | — | — | US | claimed |
| US-12559703-B2 | Fragrance composition | GIVAUDAN SA (CH) | 2026-02-24 | — | — | US | claimed |
| EP-4581114-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Novozymes A/S (DK) | 2025-07-09 | — | — | EP | claimed |
| US-20250163343-A1 | FRAGRANCE COMPOSITIONS FOR SLEEP IMPROVEMENT | INTERNATIONAL FLAVORES & FRAGRANCES INC. | 2025-05-22 | — | — | US | claimed |
| EP-4486857-A1 | FRAGRANCE COMPOSITIONS FOR SLEEP IMPROVEMENT | International Flavors & Fragrances Inc. (US) | 2025-01-08 | — | — | EP | claimed |
| CN-119156438-A | Perfume composition for sleep improvement | 国际香料和香精公司 | 2024-12-17 | — | — | CN | claimed |
| WO-2024213536-A1 | FRAGRANCE COMPOSITION | GIVAUDAN SA (CH) | 2024-10-17 | — | — | WO | claimed |
| EP-4446001-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Givaudan SA (CH) | 2024-10-16 | — | — | EP | claimed |
| WO-2024046952-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | NOVOZYMES A/S (DK) | 2024-03-07 | — | — | WO | claimed |
| US-20230399590-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | SA, GIVAUDAN (CH) | 2023-12-14 | — | — | US | claimed |
| EP-3149135-A2 | PERFUME COMPOSITIONS | Givaudan S.A. (CH) | 2017-04-05 | — | — | EP | claimed |
| US-20170073614-A1 | Perfume Compositions | GIVAUDAN SA (CH) | 2017-03-16 | — | — | US | claimed |
| WO-2016135193-A1 | A SYNERGISTIC PERFUMING COMPOSITION | FIRMENICH SA (CH) | 2016-09-01 | — | — | WO | claimed |
| WO-2015181257-A2 | PERFUME COMPOSITIONS | GIVAUDAN SA (CH) | 2015-12-03 | — | — | WO | claimed |
| JP-4518957-B2 | — | — | 2010-08-04 | — | — | JP | claimed |
| US-7384906-B2 | Aliphatic compounds as fragrants with musk characteristics | GIVANDAN SA (CH) | 2008-06-10 | — | — | US | claimed |
| EP-1565420-B1 | ALIPHATIC COMPOUNDS AS FRAGRANTS WITH MUSK CHARACTERISTICS | GIVAUDAN SA (CH) | 2006-10-18 | — | — | EP | claimed |
| US-20060052277-A1 | Aliphatic compounds as fragrants with musk characteristics | GIVAUDAN SA (CH) | 2006-03-09 | — | — | US | claimed |
| EP-1565420-A1 | ALIPHATIC COMPOUNDS AS FRAGRANTS WITH MUSK CHARACTERISTICS | Givaudan SA (CH) | 2005-08-24 | — | — | EP | claimed |
| WO-2004050595-A1 | ALIPHATIC COMPOUNDS AS FRAGRANTS WITH MUSK CHARACTERISTICS | GIVAUDAN SA (CH) | 2004-06-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12589377-B2 | Encapsulated composition comprising core-shell microcapsules and process for its preparation | CUTA, EXOC1, EXOSC10 | ADRB2 4499/4885ADRB1 4437/4885ADRB3 4625/4885 |
| US-12559703-B2 | Fragrance composition | DHCR24, OPRD1, OR10J3 | ADRB2 423/4885ADRB1 466/4885ADRB3 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.